Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features

Anti-Cancer Drugs

Volumn 20, Issue 3, 2009, Pages 197-203

  Balduzzi, Alessandra ^a,f   Montagna, Emilia ^a   Bagnardi, Vincenzo ^b,g   Torrisi, Rosalba ^a   Bertolini, Francesco ^c   Mancuso, Patrizia ^c   Scarano, Eloise ^f   Viale, Giuseppe ^d   Veronesi, Paolo ^e   Cardillo, Anna ^a   Orlando, Laura ^a   Goldhirsch, Aron ^f   Colleoni, Marco ^a  

^a Research Unit of Medical Senology   (Italy)

^b Division of Epidemiology and Biostatistics

^c Division of Hematology/Oncology   (United States)

^d Division of Pathology

^e Division of Senology   (Austria)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antiangiogenesis; Circulating endothelial cells; Endocrine receptor negative; Inflammatory breast cancer

Indexed keywords

BEVACIZUMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; MASTECTOMY; MIDDLE AGED; NITRILES; PACLITAXEL; PROGNOSIS; PROTEINURIA; RADIOTHERAPY, ADJUVANT; TRIAZOLES;

EID: 61749103127     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283264719     Document Type: Article

References (32)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiemnann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-2608.
2. Singletary S, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628-3636.
3. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer. Patients treated with multimodality therapy. J Clin Oncol 2004; 22:4067-4074.
4. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer 2007; 110:1436-1444.
5. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10:6622-6628.
6. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significant enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
7. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18:1927-1934.
8. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12: 3124-3129.
9. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
10. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
11. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC) [abstract LBA1011]: AVADO. Proc Am Soc Clin Oncol 2008; 26:158.
12. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor, vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
13. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850.
14. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
15. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62:667-672.
16. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6:835-845.
17. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87:2244-2251.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders S, Kaplan J, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
19. Kuerer HM, Newman LA, Smith TM, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
20. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
21. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res 2007; 13:5862-5868.
22. Makoul I, Klimberg S, Henry-Tillman R, Westbrook K, Korourian S, Siegel E, et al. Primary systemic therapy using docetaxel/cyclophosphamide/ bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC) [abstract 5055]. SABCS 2007.
23. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger C, et al. Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): phase Il results [abstract 14575]. Proc Am Soc Clin Oncol 2008; 26:15S.
24. Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, et al. UCLA Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract 301]. SABCS 2006.
25. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10:1706-1716.
26. Torrisi R, Orlando L, Ghisini R, Veronesi P, Intra M, Rocca A, et al. A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer. Anticancer Res 2006; 25:2861-2864.
27. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97:3658-3661.
28. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 61:4341-4344.
29. Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004; 64:4373-4377.
30. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967.
31. Gehling UM, Ergün S, Schumacher U, Wagner C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95:3106-3112.
32. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7:1194-1201.